Crossmark

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

Crossref DOI link: https://doi.org/10.1038/bmt.2016.9

Published Online: 2016-02-15

Published Print: 2016-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van Gelder, M

van Oers, M H

Alemayehu, W G

Abrahamse-Testroote, M C J

Cornelissen, J J

Chamuleau, M E

Zachée, P

Hoogendoorn, M

Nijland, M

Petersen, E J

Beeker, A

Timmers, G-J

Verdonck, L

Westerman, M

de Weerdt, O

Kater, A P
License Information

Text and Data Mining valid from 2016-02-15

Version of Record valid from 2016-02-15
More Information

Article History

Received: 10 November 2015

Revised: 22 December 2015

Accepted: 31 December 2015

First Online: 15 February 2016

Competing interests

: The authors declare no conflict of interest.

Document is current

Any future updates will be listed below